This company listing is no longer active

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Athersys onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:ATHX.Q - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2023	0	-38	-25	-26	N/A
6/30/2023	0	-47	-31	-33	N/A
3/31/2023	2	-58	-45	-45	N/A
12/31/2022	5	-73	-59	-59	N/A
9/30/2022	6	-81	-69	-66	N/A
6/30/2022	11	-84	-78	-76	N/A
3/31/2022	8	-83	-81	-79	N/A
12/31/2021	6	-87	-78	-76	N/A
9/30/2021	6	-87	-76	-74	N/A
6/30/2021	1	-94	-76	-74	N/A
3/31/2021	1	-90	-68	-67	N/A
12/31/2020	1	-79	-63	-62	N/A
9/30/2020	0	-66	-56	-55	N/A
6/30/2020	0	-56	-44	-43	N/A
3/31/2020	4	-47	-43	-42	N/A
12/31/2019	6	-45	-36	-35	N/A
9/30/2019	7	-46	-30	-30	N/A
6/30/2019	10	-44	-30	-29	N/A
3/31/2019	25	-27	-14	-13	N/A
12/31/2018	24	-24	-15	-13	N/A
9/30/2018	24	-26	-16	-15	N/A
6/30/2018	22	-24	-15	-14	N/A
3/31/2018	3	-37	-25	-24	N/A
12/31/2017	4	-32	-24	-24	N/A
9/30/2017	4	-26	-24	-24	N/A
6/30/2017	3	-25	N/A	-23	N/A
3/31/2017	3	-26	N/A	-24	N/A
12/31/2016	17	-15	N/A	-11	N/A
9/30/2016	27	-5	N/A	-10	N/A
6/30/2016	27	-5	N/A	-8	N/A
3/31/2016	27	1	N/A	-8	N/A
12/31/2015	12	-16	N/A	-14	N/A
9/30/2015	2	-27	N/A	-15	N/A
6/30/2015	1	-25	N/A	-17	N/A
3/31/2015	2	-23	N/A	-17	N/A
12/31/2014	2	-22	N/A	-26	N/A
9/30/2014	2	-25	N/A	-24	N/A
6/30/2014	3	-26	N/A	-24	N/A
3/31/2014	3	-33	N/A	-24	N/A
12/31/2013	2	-31	N/A	-23	N/A
9/30/2013	4	-24	N/A	-22	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if ATHX.Q's forecast earnings growth is above the savings rate (2.5%).

Winst versus markt: Insufficient data to determine if ATHX.Q's earnings are forecast to grow faster than the US market

Hoge groeiwinsten: Insufficient data to determine if ATHX.Q's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if ATHX.Q's revenue is forecast to grow faster than the US market.

Hoge groei-inkomsten: Insufficient data to determine if ATHX.Q's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if ATHX.Q's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Athersys Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus forecasts updated

Price target decreased to US$3.33

Consensus revenue estimates fall by 70%

Price target decreased to US$3.33

Consensus forecasts updated

Price target increased to US$5.00

Recent updates

Motion For Case Conversion Approved for Athersys, Inc.

Motion for Case Conversion Filed by Athersys, Inc.

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Athersys, Inc. announced delayed annual 10-K filing

Motion for Joint Administration Filed by Athersys, Inc.

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc.(OTCPK:ATHX) dropped from S&P TMI Index

Athersys, Inc. Receives A Delisting Determination Letter from Nasdaq

Athersys, Inc. Reports Interim Analysis Results of MASTERS-2 Clinical Study with Multistem in Ischemic Stroke

Athersys, Inc. Appoints Jane Wasman as Board Chair

Athersys, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc. Appoints Neema Mayhugh to Its Board of Directors, Nominations, Governance and Compliance Committee, Compensation Committee and Audit Committee

New major risk - Market cap size

Athersys Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Requirement

Athersys, Inc., Annual General Meeting, Sep 27, 2023

Athersys, Inc. Announces Patient Enrollment Begins in Third and Final Cohort of the Phase 2 Matrics-1 Clinical Study Evaluating Athersys' Multistem Following Hemorrhagic Trauma

Athersys Granted Clinical Type B Meeting with FDA for Masters-2 Clinical Trial Protocol Discussion

Athersys, Inc. Provides an Update on Ongoing Clinical Trials with MultiStem for the Treatment of Patients Following Hemorrhagic Trauma (MATRICS-1) and for the Treatment of Ischemic Stroke (MASTERS-2)

Athersys, Inc. Appoints Joseph Nolan to Its Board of Directors

Athersys Receives A Written Notice from Nasdaq Regarding Bid Price Requirement

CEO, Secretary recently bought US$55k worth of stock

Athersys, Inc. to Report Q3, 2022 Results on Nov 15, 2022

Athersys, Inc. Announces the Resignation of Kenneth H. Traub from the Board of Directors

Athersys Receives Non-Compliance Letter from Nasdaq

Athersys: Is Big Pharma Sleeping At The Wheel?

Athersys extends exercise period of warrants in connection with recent offering

Athersys announces 1-for-25 reverse stock split

One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher

Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents

Athersys, Inc. Announces Favorable Preclinical Results for MultiStem Treatment in Defense Department Radiation Countermeasure Study

Athersys, Inc. Appoints Kasey Rosado as Interim Chief Financial Officer

Kasey Rosado named interim CFO of Athersys

Athersys, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Athersys: Dead Man Walking

Athersys, Inc. Designates Dan Camardo as the Principal Financial Officer and Principal Accounting Officer

Athersys, Inc. Announces Board Changes

Athersys, Inc. Announces Management Changes

Athersys, Inc., Annual General Meeting, Jun 15, 2022

Consensus forecasts updated

Athersys: Focus On Stroke

Athersys, Inc. to Report Q1, 2022 Results on May 06, 2022

Price target decreased to US$3.33

Athersys - Hero Or Zero Opportunity

Consensus revenue estimates fall by 70%

Price target decreased to US$3.33

Consensus forecasts updated

Price target increased to US$5.00

Athersys, Inc. to Report Q4, 2021 Results on Mar 15, 2022

Athersys, Inc. to Present an Outlook of its Ischemic Stroke Program Including Perspectives on the Upcoming TREASURE Study Data Readout

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022

Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely

Athersys, Inc. Announces Manuscript Reporting Data from the Company’s Must-ARDS Clinical Trial

Athersys: COVID-ARDS Is The Company's Most Important Target

Price target decreased to US$3.75

Third quarter 2021 earnings released: US$0.071 loss per share (vs US$0.11 loss in 3Q 2020)

Price target decreased to US$4.67

Athersys Shares Are Ready To Rumble Following Period Of Turmoil

Consensus forecasts updated

Consensus forecasts updated

Athersys: Subgroup Analysis As A Masterstroke

New Publication Provides Further Clarity of MultiStem's Mechanism of Action on Modulating the Inflammatory Response in Critical Care Indications

Athersys, Inc. announced that it expects to receive $100 million in funding from Aspire Capital Partners, LLC

Here's Why We're Watching Athersys' (NASDAQ:ATHX) Cash Burn Situation

Consensus revenue estimates fall to US$9.42m

Full year 2020 earnings released: US$0.42 loss per share (vs US$0.29 loss in FY 2019)

Athersys, Inc. to Report Fiscal Year 2020 Results on Mar 25, 2021